| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-10-15 | Forward Pharma (Denmark) | $235.2 million | IPO | Autoimmune diseases - Neurodegenerative diseases | IPO | |
| 2014-10-15 | TC BioPharm (UK) | £100,000 (€125733) | grant | Scottish Enterprise (UK) | Cancer - Oncology | Grant |
| 2014-10-15 | Atara Biotherapeutics (USA - CA) | $ 55 millio | IPO | Cancer - Oncology - Kidney diseases - Renal diseases | IPO | |
| 2014-10-08 | Mimetas (The Netherlands) | $ 5.2 million (€4.1 million) | fundraising | Zeeuws Investerings Fonds (ZIF) (The Netherlands), Participatiemaatschapij Oost Nederland (PPM Oost) (The Netherlands), national and regional partners | Technology - Services | Fundraising |
| 2014-10-08 | PTC Therapeutics (USA - NJ) | IPO | IPO | |||
| 2014-10-07 | Atopix Therapeutics (UK) | £1.7 million (€1.98 million) + £3.7 million (€4.32 million) | grant - series A financing round | Biomedical Catalyst Fund (UK) - MPM Capital - SV Life Sciences (UK- USA) - Wellington Partners (USA) - Bessemer Partners (USA) - Red Abbey (UK) - SR One (UK) | Allergic diseases - Dermatological diseases | Series A financing round |
| 2014-10-06 | VBL Therapeutics (Israel) | $34.4 million (€ 27.5 million) | IPO | Cancer - Oncology - Immunological diseases - Inflammatory diseases | IPO | |
| 2014-09-30 | Vitamfero (France) | €2.7 million | capital increase | Go Capital (France), Pradeyrol Développement (France), Business Angels affiliated with Val de France Angels (France) CapDecisif Management (France), G1J Ile-de-France (France), individual investors | Infectious diseases | Capital increase |
| 2014-09-29 | Molmed (Italy) | capital increase | Société Générale (France) | Capital increase | ||
| 2014-09-29 | Nanovi (Denmark) | €2.7 million | fundraising | Vækstfonden (Denmark) 3Shape A/S (Denmark) | Cancer - Oncology | Fundraising |
| 2014-09-25 | Adaptimmune (UK) | $104 million (€81.4 million) | series A financing round | New Enterprise Associates (NEA) (USA - MD) OrbiMed Advisors (USA - NY) Wellington Management Company, LLP (USA - MA), Fidelity Biosciences (USA - MA), Foresite Capital Management (USA - CA), Ridgeback Capital Management (USA - TX), Novo A/S (Denmark), QVT (USA - NY), Rock Springs Capital (USA - MD), venBio Select (USA - CA), Merlin Nexus (USA - NY), University of Oxford (UK) | Cancer - Oncology | Series A financing round |
| 2014-09-25 | Videregen (UK) | £1.2 million (€1.53 million) | fundraising | SPARK Impact (UK) London Business Angels (UK) and other investors | Transplantation | Fundraising |
| 2014-09-25 | Santen Holdings (The Netherlands) | € 42 million (Approximately ¥6 billion) | capital increase | Santen Pharmaceutical (Japan) | Ophtalmological diseases | Capital increase |
| 2014-09-24 | Evotec (Germany) | €5 million | grant | German Ministry of Education and Research (BMBF) (Germany) | Neurodegenerative diseases | Grant |
| 2014-09-23 | ProQR Therapeutics (The Netherlands) | $102 million (€79.3 million) | IPO | IPO | ||
| 2014-09-23 | nLife Therapeutics (Spain) | $350,000 (€ 271,000) | grant | The Michael J. Fox Foundation - MJFF (USA) | Neurodegenerative diseases | Grant |
| 2014-09-23 | BerGenBio (Norway) | £1.6 million (NOK 16 million - € 2 million) | convertible loan | Wellcome Trust (UK) | Cancer - Oncology | Loan |
| 2014-09-23 | Foamix Pharmaceuticals (Israel - USA - NJ) | $35.7 million | IPO | IPO | ||
| 2014-09-22 | Silarus Therapeutics (USA - CA) | $ 10 million | series A financing round | GSK (UK) Avalon Venture (USA - CA) | Metabolic diseases | Series A financing round |
| 2014-09-22 | Thyritope Biosciences (USA - CA) | $ 10 million | series A financing round | GSK (UK) Avalon Venture (USA - CA) | Autoimmune diseases | Series A financing round |
